Mosunetuzumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 14, 2026

Fixed Treatment Duration Mosunetuzumab in Patients With Relapsed or Refractory Follicular Lymphoma: Perspectives From US Advanced Practice Providers.

Fixed Treatment Duration Mosunetuzumab in Patients With Relapsed or Refractory Follicular Lymphoma: Perspectives From US Advanced Practice Providers.

Journal: Journal of the advanced practitioner in oncology

Published: August 01, 2026

Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.

Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.

Journal: Human vaccines & immunotherapeutics

Published: July 30, 2026

Safety evaluation of CD3×CD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.

Safety evaluation of CD3×CD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.

Journal: BMJ open

Published: June 30, 2026

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis.

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis.

Journal: American journal of hematology

Published: June 26, 2026

Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves.

Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves.

Journal: Cureus

Published: June 22, 2026

Odronextamab: a bispecific antibody for follicular lymphoma.

Odronextamab: a bispecific antibody for follicular lymphoma.

Journal: Expert opinion on investigational drugs

Published: June 13, 2026

Odronextamab: a bispecific antibody for follicular lymphoma.

Odronextamab: a bispecific antibody for follicular lymphoma.

Journal: Expert opinion on investigational drugs

Published: June 13, 2026

A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies.

A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies.

Journal: Pathophysiology : the official journal of the International Society for Pathophysiology

Published: June 12, 2026

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.

Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: May 24, 2026

Mosunetuzumab Successfully Treated Rituximab-Refractory Lymphoma-Associated Protein-Losing Enteropathy With Concomitant Immune Thrombocytopenia in Follicular Lymphoma: A Case Report.

Mosunetuzumab Successfully Treated Rituximab-Refractory Lymphoma-Associated Protein-Losing Enteropathy With Concomitant Immune Thrombocytopenia in Follicular Lymphoma: A Case Report.

Journal: EJHaem

Published: April 24, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

Showing 1-12 of 161

Last Updated: 09/26/2026